Top

Published in:

01-11-2014 | Rapid Communication

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Authors: Alfred I. Neugut, Grace Clarke Hillyer, Lawrence H. Kushi, Lois Lamerato, Nicole Leoce, Christine B. Ambrosone, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Dawn L. Hershman

Published in: Breast Cancer | Issue 6/2014

Abstract

One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35:121–36.PubMedCrossRef

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.PubMedCrossRef

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–20.PubMedCrossRef

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29–36.PubMedCrossRef

Pivot X, Romieu G, Bonnefoi H, et al. PHARE trial results comparing 6–12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol. (in press).

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef

Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639–46.PubMedCrossRef

10.

Bickell NA, McEvoy MD. Physicians’ reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003;41:442–6.PubMed

11.

Silliman RA, Guadagnoli E, Weitberg AB, Mor V. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989;44:M46–50.PubMedCrossRef

12.

Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99:313–21.PubMedCrossRef

13.

Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65:1353–60.PubMedCrossRef

14.

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Nathanson SD, Ambrosone CB, et al. The breast cancer quality of care study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J. 2012;18:203–13.PubMedCrossRefPubMedCentral

15.

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Non-initiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol. 2012;30:3800–9.PubMedCrossRefPubMedCentral

16.

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2012;134:419–28.PubMedCrossRefPubMedCentral

17.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef

18.

Coulson SG, Kumar VS, Manifold IM, Hatton MQ, Ramakrishnan S, Dunn KS, et al. Review of testing and use of adjuvant trastuzumab across a cancer network–are we treating the right patients? Clin Oncol (R Coll Radiol). 2010;22:289–93.CrossRef

19.

Barron JJ, Cziraky MJ, Weisman T, Hicks DG. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009;14:760–8.PubMed

20.

Montserrat M, Leveque D, Barthelemy P, Bergerat JP. Duration of adjuvant trastuzumab treatment in routine practice. Anticancer Res. 2012;32:4585–8.PubMed

21.

Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014;32:927–34.PubMedCrossRef

22.

Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6.PubMedCrossRef

23.

Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer. 2009;115:3848–57.PubMedCrossRefPubMedCentral

24.

Balasubramanian BA, Gandhi SK, Demissie K, August DA, Kohler B, Osinubi OY, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–8.PubMed

25.

Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009;115:2999–3008.PubMedCrossRef

26.

Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J Clin Oncol. 2007;25:3699–704.PubMedCrossRef

Title: Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer
Authors: Alfred I. Neugut
Grace Clarke Hillyer
Lawrence H. Kushi
Lois Lamerato
Nicole Leoce
Christine B. Ambrosone
Dana H. Bovbjerg
Jeanne S. Mandelblatt
Dawn L. Hershman
Publication date: 01-11-2014
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-014-0543-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Acknowledgement to reviewers 2014

Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?

Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis

Re: Comparison of conventional and automated breast volume ultrasound in the description and characterization of solid breast masses based on BI-RADS features

Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer

Osteopoikilosis masquerading as osseous metastases in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer